ClinicalTrials.gg
CompletedNCT04843709Updated May 15, 2026

A Study of MRG004A in Patients With Tissue Factor Positive Advanced or Metastatic Solid Tumors

A Phase 1/2 interventional study of MRG004A in Advanced or Metastatic Solid Tumors, sponsored by Lepu Biopharma Co., Ltd.. Completed at 9 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-15.

Sponsored by Lepu Biopharma Co., Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Mar 2024, 2 years 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
39
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The objective of this study is to evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of MRG004A in patients with Tissue Factor positive advanced or metastatic solid tumors.

Read the detailed description

This study consists of two parts. Part A is a dose escalation study to determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of MRG004A. Part B is a disease specific multi-cohort dose expansion study to further assess the efficacy and safety of MRG004A at confirmed RP2D.

02

Conditions studied

  • Advanced or Metastatic Solid Tumors

Keywords

  • MRG004A
  • Antibody drug conjugate (ADC)
  • Tissue factor
  • Solid tumors
03

In context

Lead sponsor

Lepu Biopharma Co., Ltd. is the lead sponsor of 16 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Understands and provides written and willing to follow the requirements specified in protocol.
  2. Age ≥18 years.
  3. ≥6 months.
  4. For Part B patients, documented Tissue Factor (TF) presence in tumor specimens obtained from archival or re-biopsy specimens by immunohistochemistry (IHC) protein expression.
  5. Must have or cytologically confirmed unresectable or cancer with documented disease progression during prior therapy, or relapse or progression following approved standard therapy for their tumor types- Part A and Part B.
  6. Part B: Patients who have documented progression during or relapse following standard therapy, no further treatment options that are known to improve survival, and participation in a clinical trial is a reasonable therapeutic option.
  7. Patients must have per v1.1.
  8. performance status of 0 or 1.
  9. Acceptable bone marrow, hepatic, cardiac, renal, and coagulation function.
  10. A negative serum pregnancy test if female and aged between 18-55 years old.
  11. Patients, both females and males, of must agree to use adequate during and for 180 days after the last infusion of MRG004A.

Exclusion criteria

Exclusion Criteria:

  1. Archival or tumor shows TF IHC membrane or cytosolic score of zero, no TF-positive expression or no TF-positive staining in Part B patients.
  2. Toxicities (except alopecia \& fatigue) due to prior antitumor therapy are greater than v5.0 Grade 1.
  3. Toxicities due to prior radiotherapy that have not resolved to Grade ≤ 1 CTCAE v5.0 at least 21 days prior to the first treatment.
  4. Untreated, unstable or uncontrolled central nervous system (CNS) .
  5. Any other type of anti-cancer therapy within 21 days of the first dose of study treatment. Use of any other type of anti-cancer treatment is prohibited throughout the study.
  6. Patients with increased bleeding risk.
  7. Presence of severe cardiac dysfunction.
  8. Pulmonary embolism or deep vein thrombosis within 3 months prior to the first dose of study drug.
  9. Concurrent within 5 years prior to entry.
  10. Uncontrolled or poorly controlled hypertension.
  11. History of ventricular tachycardia, or torsade des pointes.
  12. History of moderate to severe dyspnea at rest.
  13. Major surgery within 4 weeks of the first dose of study treatment and not fully recovered. Minor surgery within 2 weeks prior to study treatment.
  14. Known allergic reactions to any component or of MRG004A or known allergic reactions to other prior anti-TF (including ) or other monoclonal antibody ≥ Grade 3.
  15. Patients who have any known liver disease, including chronic , , hepatic disorders, primary biliary cirrhosis or sclerosing cholangitis; Patients who have concurrent, serious, uncontrolled infections or known infection with , or have a diagnosed acquired immunodeficiency syndrome (AIDS); or an uncontrolled autoimmune disease, or have undergone organ transplant.
  16. Active uncontrolled bacterial, viral, fungal, rickettsial, or parasitic infection.
  17. Use of systemic within 4 weeks prior to the first dose of treatment.
  18. Use of strong inhibitors or inducers with MRG004A.
  19. Other excluded medications or treatment: therapeutic anti-coagulative, or long-term anti- treatment; multivitamins, calcium, vitamin D, and prophylactic anti-RANKL (denosumab) and zoledronic acid therapies for bone metastases are allowed.
  20. Any patient with a positive pregnancy or is breast-feeding.
  21. Any severe and/or uncontrolled systemic disease that at the discretion of investigator and sponsor makes it undesirable for the patient to participate in this study.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    MRG004A

    All patients in Part A (dose escalation) and Part B (dose expansion) will be administrated MRG004A on Day 1 of every 3 weeks (21-day cycle).

    Drug: MRG004A

Interventions

  • DrugMRG004A

    Administrated intravenously

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose (MTD)

    The highest dose confirmed wherein less than 2 out of 6, or \< 33% of evaluable patients in a treatment cohort experiences dose-limiting toxicity (DLT).

    Time frame: DLT will be evaluated during the first treatment cycle (Day 1-21)

  2. Recommended Phase II Dose (RP2D)

    The dose level of MRG004A recommended for further clinical studies based on assessment of the safety, efficacy and PK data from Part A of this study.

    Time frame: Baseline to study completion (up to 24 months)

  3. Objective Response Rate (ORR)

    The proportion of patients who achieve complete response (CR) or partial response (PR) as assessed by the Independent Central Review (ICR).

    Time frame: Baseline to study completion (up to 24 months)

  4. Adverse Events (AEs)

    Any reaction, side effect, or untoward event that occurs during the course of the clinical trial whether or not the event is considered related to the study drug.

    Time frame: From signing informed consent until 45 days after the last dose of MRG004A

Secondary outcomes

  1. Duration of Response (DoR)

    The time interval between the date of the earliest qualifying response and the date of disease progression or death for any cause, whichever occurs earlier.

    Time frame: Baseline to study completion (up to 24 months)

  2. Disease Control Rate (DCR)

    The proportion of patients who achieve CR, PR, or stable disease (SD) ≥ 6 weeks based on RECIST v1.1.

    Time frame: Baseline to study completion (up to 24 months)

  3. Progression Free Survival (PFS)

    The time from the date of first study dose to disease progression or death whichever occurs first.

    Time frame: Baseline to study completion (up to 24 months)

  4. Overall Survive (OS)

    The time from start of study treatment to date of death as a result of any cause.

    Time frame: Baseline to study completion (up to 24 months)

  5. Pharmacokinetics (PK) Parameter of MRG004A: Cmax

    Maximum observed plasma concentration.

    Time frame: Baseline to 30 days after the last dose of study treatment

  6. Pharmacokinetics (PK) Parameter of MRG004A: Tmax

    Time to reach the maximum plasma concentration.

    Time frame: Baseline to 30 days after the last dose of study treatment

  7. Pharmacokinetics (PK) Parameter of MRG004A: AUClast

    Area under the plasma concentration-time curve from time 0 to the time of last quantifiable concentration.

    Time frame: Baseline to 30 days after the last dose of study treatment

  8. Incidence of anti-drug antibody (ADA)

    The proportion of patients with positive ADA immunogenicity results.

    Time frame: Baseline to 30 days after the last dose of study treatment

07

Study locations

9 sites
  • Chao Family Comprehensive Cancer Center
    Orange, California 92868-3201, United States
  • Memorial Sloan Kettering 60th Street Outpatient Center
    New York, New York 10065, United States
  • Gabrail Cancer Center Research
    Canton, Ohio 44718, United States
  • The Christ Hospital Cancer Center
    Cincinnati, Ohio 45219, United States
  • Gettysburg Cancer Center
    Gettysburg, Pennsylvania 17325, United States
  • Virginia Cancer Specialists
    Fairfax, Virginia 22031, United States
  • Hunan Cancer Hospital
    Changsha, Hunan 410013, China
  • Fudan University Shanghai Cancer Center
    Shanghai, Shanghai Municipality 201321, China
  • The First Affiliated Hospital, College of Medicine, Zhejiang University
    Hangzhou, Zhejiang 310003, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2021 to primary completion in Mar 2024, 31 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2021
First posted
Apr 13, 2021
StartActual
Jul 26, 2021
Primary completionActual
Mar 20, 2024
CompletionActual
Jul 26, 2024
Last update
May 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04843709
Lead sponsor
Lepu Biopharma Co., Ltd.
Responsible party
Sponsor
First posted
Apr 13, 2021
Start date
Jul 26, 2021
Primary completion
Mar 20, 2024
Completion
Jul 26, 2024
Last update
May 15, 2026

Study contacts

Nashat Y Gabrail, MD
principal investigator · Gabrail Cancer Center Research

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion